FDA新藥審批流程簡(jiǎn)述(中英文)

1、精選優(yōu)質(zhì)文檔-傾情為你奉上FDA新藥審批流程 美國(guó)的新藥審批可以說(shuō)是世界上最嚴(yán)格和規(guī)范的，作為一個(gè)公司通常需要花費(fèi)5億美元資金，用 12到15年的時(shí)間才能將一個(gè)新藥從試驗(yàn)室走入市場(chǎng)。在5000個(gè)臨床前化合物中大約只有5個(gè)化合物可以進(jìn)入臨床試驗(yàn)（Clinical Trials），而這5個(gè)化合物中只有一個(gè)才能被批準(zhǔn)用于臨床治療病人，成為真正的藥物。 從一個(gè)實(shí)驗(yàn)室發(fā)現(xiàn)的新化合物發(fā)展成為一個(gè)治療疾病的藥物，需要經(jīng)過(guò)如下開(kāi)發(fā)階段：一、 臨床前試驗(yàn)將一個(gè)新發(fā)現(xiàn)的化合物經(jīng)過(guò)實(shí)驗(yàn)室和動(dòng)物試驗(yàn)，證明該化合物針對(duì)特定目標(biāo)疾病具有生物活性，并且要評(píng)估該化合物的安全性。二、 新藥臨床研究申請(qǐng)當(dāng)一個(gè)化合物通過(guò)了臨床前試

2、驗(yàn)后，需要向FDA提交新藥臨床研究申請(qǐng)，以便可以將該化合物應(yīng)用于人體試驗(yàn)。如果在提交申請(qǐng)后30天內(nèi)FDA沒(méi)有駁回申請(qǐng)，那么該新藥臨床研究申請(qǐng)即被視為有效，可以進(jìn)行人體試驗(yàn)。新藥臨床研究申請(qǐng)需要提供先前試驗(yàn)的材料；以及計(jì)劃將在什么地方，由誰(shuí)以及如何進(jìn)行臨床試驗(yàn)的說(shuō)明；新化合物的結(jié)構(gòu)；投藥方式；動(dòng)物試驗(yàn)中發(fā)現(xiàn)的所有毒性情況；該化合物的制造生產(chǎn)情況。所有臨床方案必須經(jīng)過(guò)機(jī)構(gòu)審評(píng)委員會(huì)（Institutional Revuew Board，IRB）的審查和通過(guò)。每年必須向FDA和IRB 匯報(bào)一次臨床試驗(yàn)的進(jìn)程和結(jié)果。三、 一期臨床試驗(yàn)這一階段的臨床試驗(yàn)一般需要征集20100名正常和健康的志愿者進(jìn)行試驗(yàn)

3、研究。試驗(yàn)的主要目的是提供該藥物的安全性資料，包括該藥物的安全劑量范圍。同時(shí)也要通過(guò)這一階段的臨床試驗(yàn)獲得其吸收、分布、代謝和排泄以及藥效持續(xù)時(shí)間的數(shù)據(jù)和資料。 四、二期臨床試驗(yàn) 這一期的臨床試驗(yàn)通常需要征集100500名相關(guān)病人進(jìn)行試驗(yàn)。其主要目的是獲得藥物治療有效性資料。五、三期臨床試驗(yàn) 這一期的臨床試驗(yàn)通常需 10005000名臨床和住院病人，多在多個(gè)醫(yī)學(xué)中心進(jìn)行，在醫(yī)生的嚴(yán)格監(jiān)控下，進(jìn)一步獲得該藥物的有效性資料和鑒定副作用，以及與其他藥物的相互作用關(guān)系。該階段試驗(yàn)一般采取多中心，安慰劑（或/和有效對(duì)照劑）對(duì)照和雙盲法試驗(yàn)。第三期臨床試驗(yàn)是整個(gè)臨床試驗(yàn)中最主要的一步。 六、新藥申請(qǐng)?jiān)谕瓿?/p>

4、所有三個(gè)階段的臨床試驗(yàn)并分析所有資料及數(shù)據(jù)，如證明該藥物的安全性和有效性，則可以向 FDA提交新藥申請(qǐng)。新藥申請(qǐng)需要提供所有收集到的科學(xué)資料。通常一份新藥申請(qǐng)材料可多達(dá) 頁(yè)，甚至更多！按照法規(guī)，F(xiàn)DA應(yīng)在6個(gè)月內(nèi)審評(píng)完新藥申請(qǐng)。但是由于大部分申請(qǐng)材料過(guò)多，而且有許多不規(guī)范，因此往往不能在這么短的時(shí)間內(nèi)完成。 1999年對(duì)于單個(gè)化學(xué)分子藥的審評(píng)時(shí)間平均為 12.6個(gè)月。 七、批準(zhǔn)上市 一旦FDA批準(zhǔn)新藥申請(qǐng)后，該藥物即可正式上市銷(xiāo)售，供醫(yī)生和病人選擇。但是還必須定期向FDA呈交有關(guān)資料，包括該藥物的副作用情況和質(zhì)量管理記錄。對(duì)于有些藥物FDA還會(huì)要求做第四期臨床試驗(yàn)，以觀測(cè)其長(zhǎng)期副作用情況。（中

5、國(guó)醫(yī)藥市場(chǎng)信息2002第2期16頁(yè)） The Food and Drug Administration (FDA) regulates the development of novel drugs. Both prescription and over-the-counter drugs are regulated by the Center for Drug Evaluation and Research (CDER). CDER has been established to ensure that drug products are safe and effective. All new

6、 drug products must undergo a rigorous process of pre-clinical and clinical evaluation. According to a 1999 report from PhRMA, it takes 15 years and $500 million for an experimental drug to travel from the lab bench to the patient. For every 5000 compounds that enter pre-clinical testing, only five

7、will continue on to clinical trials in humans and only one will be approved for marketing in the United States. After each stage of development, the sponsor of the new product meets with the FDA to determine next steps and establish end points for future trials. Similar processes are required in oth

8、er countries. Preclinical Testing. A pharmaceutical or biotechnology company conducts laboratory and animal studies to demonstrate biological activity of the compound against the targeted disease, and the compound is evaluated for safety. Investigational New Drug Application (IND). After completing

9、preclinical testing, the company files an IND with the FDA to begin to test the drug in humans. The IND becomes effective if the FDA does not disapprove it within 30 days. The IND shows results of previous experiments and studies; how, where and by whom the new studies will be conducted; the chemica

10、l structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. The IND must be reviewed and approved by the Institutional Review Board (IRB) where the studies will be conducted, and progress reports on clinical

11、 trials must be submitted to the FDA at least once annually. Phase I Human Clinical Trials. These tests involve approximately 20 to 80 normal, healthy volunteers. These tests study a drugs safety profile , including the safe dosage range. The studies also analyse how a drug is absorbed, distributed,

12、 metabolised and excreted, and the duration of its action. Phase II Human Clinical Trials. Controlled studies of approximately 100 to 300 volunteer patients (people with disease being treated) to assess the drugs effectiveness and further analyse safety. Dose ranges may also be analysed during Phase

13、 II studies. More than one Phase II study may be conducted. Phase III Clinical Trials. Approximately 1,000 to 3,000 patients in clinics and hospitals. This phase is used to determine whether the drugs effectiveness is statistically significant. Patients are continuously monitored for safety or adver

14、se reactions. Typically, more than one Phase III study is conducted. New Drug Application (NDA). Following successful completion of all three phases of human clinical trials, the company analyses all of the data and files an NDA with the FDA if the data successfully demonstrate safety and effectiven

15、ess. The NDA must contain all of the scientific information that the company has gathered on the compound. NDAs can exceed 100,000 pages or more. By legislation, the FDA is allowed six months to review an NDA filing. In 2000, the average review time for approved products was 16 months. FDA Panel Rev

16、iew. Once CDER has reviewed the NDA, the product's sponsor presents the data to a panel of experts. The members of the panel may ask for clarification of specific data points, request explanations for certain outcomes or events observed in the trial or pose questions on potential issues that may occur if the product is approved for marketing. The members of the panel then vote in favour of or against recommending marketing approv